申请人:Pennell Andrew M.K.
                            
                            
                                公开号:US20100240618A1
                            
                            
                                公开(公告)日:2010-09-23
                            
                            Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.